NAD+ side-effects: what the literature notes

People reasonably want to know whether NAD+ is safe before they spend on it. This post summarises what published studies note about tolerability across the routes, and is careful about the limits of that evidence. It is editorial commentary, not medical advice. If you experience any symptom you are concerned about, speak to a qualified healthcare professional.

What the supplement trials report

For the oral precursors NMN and NR, the human trials conducted so far generally describe the compounds as well tolerated over the studied periods. Where effects are noted, they tend to be mild and infrequent: some participants report nausea, digestive discomfort or headache, often at rates not far above placebo. These studies were typically short, ran in modest numbers of participants, and were not designed to detect rare or long-term effects.

That is the key caveat. “Well tolerated in a 12-week trial of a few dozen people” is genuinely reassuring about short-term tolerability and genuinely silent about long-term safety. There are no large long-term randomised trials establishing the multi-year safety profile of these supplements.

IV and injection routes

IV NAD+ has a different side-effect profile because of how it is delivered. The most commonly reported experiences are sensations during the infusion itself, such as flushing, chest tightness or nausea, which tend to track how fast the drip runs. This is precisely why clinics administer it slowly over several hours rather than quickly. We cover the format trade-offs in IV NAD+ in the UK and NAD+ injection vs IV.

Because IV and injection NAD+ are private clinical services rather than self-managed supplements, the practitioner administering them carries responsibility for screening and monitoring. That clinical oversight is part of what the higher cost buys, as discussed in NAD+ cost in the UK.

Why “no serious effects reported” is not “proven safe”

It is tempting to read a clean trial summary as a clean bill of health. It is not. Small short trials cannot rule out uncommon effects, interactions with medicines, or risks that only appear with prolonged use. The category is young, and the long-term human safety data simply does not yet exist at the scale that would let anyone make strong safety claims either way.

Studies suggest short-term tolerability is good; studies do not prove long-term safety. Both halves of that sentence matter.

Who should be especially cautious

This is general editorial framing, not personal advice, but it is reasonable to note that people who are pregnant or breastfeeding, who take prescription medication, or who have an existing health condition have the strongest case for talking to a healthcare professional before starting any NAD+ product. Supplements and infusions can interact with circumstances a label cannot see. Your prescriber or doctor, not a website, is the right person to make that call for you.

Read next

For the wider context, see NAD+ in the UK: the landscape explained. For the supplement label checklist, see best NAD+ supplement UK. The NAD+ sub-hub links every route, and the NMN sub-hub tracks the evolving regulatory status of the most-discussed precursor.